Phreesia PHR 深 滬
已收盤 10-31 16:00:00 美东时间
22.64
-0.020
-0.09%
華盛通- 最 高23.78
- 今 開22.74
- 成交量 98.26万股
- 最 低 22.61
- 昨 收 22.66
- 總市值 13.56亿
- 52周最高 32.76
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 17.07
- 委 比 84.95%
- 總股本 5991.45万
- 歷史最高 81.592
- 量 比 2.49
- 振 幅 5.16%
- 歷史最低 12.05
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Pharming Group N.V. announces that its management, including CEO Fabrice Chouraqui, will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025. Chouraqui will join a Fireside Chat Q&A session on November 19 at 10:00 GMT/11:00 CET. The presentation will be available via live webcast and replay on Pharming’s website. For more information or to schedule a meeting, contact Investor Relations at investor@pharmin...
10-30 07:00
A Preview Of Teladoc Health's Earnings
Teladoc Health (NYSE:TDOC) is gearing up to announce its quarterly earnings on ...
10-29 05:03
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming Group N.V. announces it will report its preliminary Q3 2025 financial results and provide a business update on November 6, 2025. A conference call and webcast for analysts and investors will be held at 13:30 CET/07:30 am ET on the same day. Participants must register in advance via provided links to access the call or webcast. The company will only take questions from dial-in attendees. The webcast will also be available on Pharming's we...
10-23 06:00
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Pharming Group N.V. announced that 12 abstracts, including new clinical and economic data for RUCONEST® and Joenja®, have been accepted for presentation at the ACAAI 2025 Annual Meeting. RUCONEST® focuses on hereditary angioedema (HAE) treatment, while Joenja® highlights real-world effectiveness in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The company emphasizes its commitment to advancing patient care and looks forward t...
10-20 06:00
Pharming Group promoted to the Euronext AMX® index
Pharming Group N.V. has been promoted to the Euronext AMX (MidCap) index, effective September 22, 2025, reflecting its strong growth momentum. The company, which focuses on rare diseases, aims to enhance visibility and attract investors, supporting its goal of becoming a leading global rare disease company.
09-10 05:00
Phreesia Analysts Raise Their Forecasts After Q2 Results
Phreesia, Inc. (NYSE:PHR) posted mixed results for the second quarter on Thursd...
09-06 03:07
Analysts Weigh Integration Risks As Phreesia Expands With New Deal
Phreesia gains analyst support with price target hikes, though integration risks and modest guidance raise tempered investor enthusiasm.
09-05 23:23
Needham Maintains Buy on Phreesia, Raises Price Target to $35
Needham analyst Ryan MacDonald maintains Phreesia (NYSE:PHR) with a Buy and raises the price target from $29 to $35.
09-05 18:52
Phreesia Reports First Net Income Positive Quarter
Phreesia ( ($PHR) ) has released its Q2 earnings. Here is a breakdown of the in...
09-05 11:54
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
